Previous 10 | Next 10 |
PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) ...
Cellectis (CLLS): Q1 Non-GAAP EPS of -$0.26 beats by $0.52; GAAP EPS of -$0.28 beats by $0.73.Revenue of $27.97M (-46.1% Y/Y) beats by $19.88M.Press Release For further details see: Cellectis EPS beats by $0.52, beats on revenue
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers Five partnered allogeneic CAR-T product candidates in clinical dev...
NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS). Dear Shareholders, In the context of the Covid-19 pandemic and in accordance with Ordinance no. 2020-321 of March 25, 2020, the provisions of which were extended until July 31, 2021 by Dec...
Gainers: [[CENX]] +3.5%. [[PLBY]] +2.9%. [[CLLS]] +2.7%. [[RAIL]] +2.6%. [[SGMS]] +2.0%.Losers: [[STKL]] -4.5%. [[MVIS]] -3.3%. [[LNDC]] -3.2%. [[CVET]] -3.2%. [[BRY]] -2.8%. For further details see: CENX, CLLS, STKL and LNDC among after-hours movers
Cellectis (CLLS) has completed sales of approx. $47M of ADS pursuant its ATM program established on March 29, through Jefferies, acting as sales agent. Each ADS represents one ordinary share. In the ATM Sales, an aggregate of ~2.4M new ADSs and the same number of new ordinary shares have been...
NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic C...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Hello, InvestorPlace Readers! This is the second installment of our new “How to Invest” series. You can see the first here: The Ultimate Guide to Investing in Growth Stocks . We’ll be covering inv...
NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic C...
Calyxt has changed its operating strategy to a more conventional agri-bio seed/trait model similar to those pursued by established agri-bio names like Bayer and Corteva. Calyxt is targeting new high-risk/high-reward market opportunities including winter oats, hemp, and soybeans with s...
News, Short Squeeze, Breakout and More Instantly...
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or months if left untreated 1 There is an urgent need to develop new therapies for ALL for patients who are not candidates for hematopoietic stem cell transpl...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...